HENGRUI PHARMA(01276)

46.120-1.820-3.80%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Movement Alert｜HENGRUI PHARMA Falls 3.05% in Regular Trading, Mid-Year Earnings Under Pressure Amid Broad Pharma Sector Weakness
  Market Focus · 59 minutes ago
  Movement Alert｜HENGRUI PHARMA Falls 3.05% in Regular Trading, Mid-Year Earnings Under Pressure Amid Broad Pharma Sector Weakness
- Hengrui Pharma's Interim Report Falls Flat: Legacy Blockbusters Fade as Revenue Posts First Half-Year Decline in Four Years
  Deep News · 08-27
  Hengrui Pharma's Interim Report Falls Flat: Legacy Blockbusters Fade as Revenue Posts First Half-Year Decline in Four Years
- Movement Alert｜HENGRUI PHARMA Rises 3.04% in Regular Trading, GIC Private Limited Consecutively Increases Stake to 17.19%
  Market Focus · 08-27
  Movement Alert｜HENGRUI PHARMA Rises 3.04% in Regular Trading, GIC Private Limited Consecutively Increases Stake to 17.19%
- Singapore Sovereign Fund Boosts Stake in Chinese Drugmaker with HK$185 Million Share Purchase
  Deep News · 08-27
  Singapore Sovereign Fund Boosts Stake in Chinese Drugmaker with HK$185 Million Share Purchase
- JPMorgan Chase & Co.'S Short Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Increases to 3.72% on August 21 from 2.57% - HKEX
  THOMSON REUTERS · 08-26
  JPMorgan Chase & Co.'S Short Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Increases to 3.72% on August 21 from 2.57% - HKEX
- Singapore's GIC Boosts Stake in Hengrui Pharma With HK$185 Million Share Purchase
  Stock News · 08-25
  Singapore's GIC Boosts Stake in Hengrui Pharma With HK$185 Million Share Purchase
- HENGRUI PHARMA: GIC Private Limited Acquires Shares, Long Position Rises to 15.7%
  HK Disclosure · 08-25
  HENGRUI PHARMA: GIC Private Limited Acquires Shares, Long Position Rises to 15.7%
- Chinese Drug Regulator Accepts Hengrui Pharma's Drug Marketing Application for HRG2010 Capsules
  MT Newswires Live · 08-25
  Chinese Drug Regulator Accepts Hengrui Pharma's Drug Marketing Application for HRG2010 Capsules
- HENGRUI PHARMA's HRG2010 Capsule Marketing Application Accepted by NMPA
  Stock News · 08-24
  HENGRUI PHARMA's HRG2010 Capsule Marketing Application Accepted by NMPA
- Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to HK$82.18 From HK$87.49, Keeps at Buy
  MT Newswires Live · 08-24
  Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to HK$82.18 From HK$87.49, Keeps at Buy
- Hengrui Pharma's Half-Year Report: Heavy Spending Fails to Drive Growth as Former Sector Leader Struggles with Revenue Without Profit Expansion
  Deep News · 08-24
  Hengrui Pharma's Half-Year Report: Heavy Spending Fails to Drive Growth as Former Sector Leader Struggles with Revenue Without Profit Expansion
- Movement Alert｜HENGRUI PHARMA Falls 3.03% in Regular Trading, BOCOM International Cuts Target Price Citing Continued Pressure on Legacy Products
  Market Focus · 08-24
  Movement Alert｜HENGRUI PHARMA Falls 3.03% in Regular Trading, BOCOM International Cuts Target Price Citing Continued Pressure on Legacy Products
- Hengrui Pharma's Growth Architecture Shifts: Second Growth Engine Accelerates as Global Valuation Framework Expands
  Stock News · 08-23
  Hengrui Pharma's Growth Architecture Shifts: Second Growth Engine Accelerates as Global Valuation Framework Expands
- Hengrui Pharma Gets Nod to Trial SHR-8203 Injection
  MT Newswires Live · 08-21
  Hengrui Pharma Gets Nod to Trial SHR-8203 Injection
- Hengrui Pharma Unit Gets China Nod for Lupus Drug Trial
  MT Newswires Live · 08-21
  Hengrui Pharma Unit Gets China Nod for Lupus Drug Trial
- Movement Alert｜HENGRUI PHARMA Declines 3.18% in Regular Trading, Extending Sell-Off on Weak H1 Earnings Quality
  Market Focus · 08-21
  Movement Alert｜HENGRUI PHARMA Declines 3.18% in Regular Trading, Extending Sell-Off on Weak H1 Earnings Quality
- Hengrui Pharmaceuticals Unit Gets China Marketing Nod for Paroxysmal Nocturnal Hemoglobinuria Drug
  MT Newswires Live · 08-20
  Hengrui Pharmaceuticals Unit Gets China Marketing Nod for Paroxysmal Nocturnal Hemoglobinuria Drug
- Jiangsu Hengrui Pharmaceuticals- Nmpa Notice Approving Developed Class 1 Innovative Drug Licancopan Fumarate (Hrs-5965) Capsules for Marketing
  THOMSON REUTERS · 08-20
  Jiangsu Hengrui Pharmaceuticals- Nmpa Notice Approving Developed Class 1 Innovative Drug Licancopan Fumarate (Hrs-5965) Capsules for Marketing
- HENGRUI PHARMA (01276) Gets Clinical Trial Approval for SHR-7012 Injection Targeting Cutaneous Lupus Erythematosus
  Stock News · 08-20
  HENGRUI PHARMA (01276) Gets Clinical Trial Approval for SHR-7012 Injection Targeting Cutaneous Lupus Erythematosus
- Jiangsu Hengrui Hong Kong Shares Hit Record Low on Quarterly Profit Miss
  Reuters · 08-20
  Jiangsu Hengrui Hong Kong Shares Hit Record Low on Quarterly Profit Miss
Company Profile
Company Name
HENGRUI PHARMA
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.hrs.com.cn
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company mainly engaged in the research, development, production and sales of drugs. The Company focuses on the field of oncology, covering kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, hormone receptor regulation, deoxyribonucleic acid (DNA) repair and epigenetics, supportive care and other research areas. The Company's products include anti-tumor, analgesic anesthesia and contrast agents, which are used in autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, blood diseases, pain management, neurological diseases, ophthalmology, nephrology and other fields. The Company mainly conducts its businesses in domestic and foreign markets.
- 08-19
  Interim Report
  2026 INTERIM REPORT
  2026 INTERIM REPORT
- 08-19
  Interim Report
  INTERIM RESULTS ANNOUNCEMENT FORTHE SIX MONTHS ENDED JUNE 30, 2026
  INTERIM RESULTS ANNOUNCEMENT FORTHE SIX MONTHS ENDED JUNE 30, 2026
- 03-26
  Annual Report
  2025 ANNUAL REPORT
  2025 ANNUAL REPORT

1D
5D
Day
Week
Month

Loading ...

High

47.940

Open

47.940

Volume%

0.87

Low

45.900

47.940

T/O Rate

0.95%

To The Moon

HENGRUI PHARMA(01276)

Company Profile

Most Discussed